Goodrx Holdings, Inc. · NASDAQ:GDRX
Goodrx — Q2 2023 Earnings Presentation
24 slides from Goodrx's earnings presentation, Aug 9, 2023
Slide 1: Q2 2023 Earnings Presentation
Q2 2023 Earnings Presentation August 9, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements,
Slide 3: Scott Wagner, Interim CEO
Scott Wagner Interim CEO
Slide 4: Strengths for us to build from
Strengths for us to build from Powerful Value Proposition Massive Scale + Impact • High consumer and provider Net Promoter Scores (NPS)1 25M+ 1.5M+ consumers used GoodRx prescribers with a • Ability to drive almost $15B of consumer for prescription savings patient who has used in LTM3 GoodRx in LTM4
Slide 5: We are rebuilding momentum in the business
“ We are rebuilding momentum in the business financially and operationally with an eye toward compounding growth ” in 2024 and beyond. - Scott Wagner, Interim Chief Executive Officer 5
Slide 6: Four key areas we're prioritizing and focused on
Four key areas we’re prioritizing and focused on: 1 2 3 4 ___________________________ ___________________________ ___________________________ ___________________________ Make sure we have Hone our short- and Scale our pharma Put our combined the strongest medium-term manufacturer efforts against our
Slide 7: Four key areas we're prioritizing and focused on
Four key areas we’re prioritizing and focused on: 1 2 3 4 ___________________________ ___________________________ ___________________________ ___________________________ Make sure we have Hone our short- and Scale our pharma Put our combined the strongest medium-term manufacturer efforts against our
Slide 8: Four key areas we're prioritizing and focused on
Four key areas we’re prioritizing and focused on: 1 2 3 4 ___________________________ ___________________________ ___________________________ ___________________________ Make sure we have Hone our short- and Scale our pharma Put our combined the strongest medium-term manufacturer efforts against our
Slide 9: Four key areas we're prioritizing and focused on
Four key areas we’re prioritizing and focused on: 1 2 3 4 ___________________________ ___________________________ ___________________________ ___________________________ Make sure we have Hone our short- and Scale our pharma Put our combined the strongest medium-term manufacturer efforts against our
Slide 10: Karsten Voermann, CFO
Karsten Voermann CFO
Slide 11: Financials: PTR and Pharma Manufacturer Solutions Revenue
Financials Prescription Transactions Revenue (PTR) Pharma Manufacturer Solutions Revenue • Second quarter PTR increased 2% year-over-year to $136.5 • Second quarter pharma manufacturer solutions revenue declined million due primarily to a 5% increase in Monthly Active 8% year-over-year to $24.3 mill
Slide 12: Financials: Subscription and Other Revenue
Financials Subscription Revenue Other Revenue • Second quarter subscription revenue decreased 8% year-over- • Second quarter other revenue remained relatively flat year-over- year to $23.9 million, due primarily to a decrease in the number year at $4.9 million of subscription plans, where the majori
Slide 13: Financials: Costs & Operating Expenses
Financials (dollars in millions) Q2 ‘23 Q2 ‘22 Costs & Operating Expenses Q2 ’23 Q2 ‘22 % Change % Revenue % Revenue Notes Decrease in fulfillment costs for Cost of Revenue $16.3 $18.0 (9%) 9% 9% certain solutions provided to customers under our pharma manufacturer solutions offering associated with
Slide 14: Financials: Net Income and Adjusted Net Income
Financials Net Income (Loss) Adjusted Net Income1 • Second quarter net income was $58.8 million compared to a net • Second quarter Adjusted Net Income was $28.4 million loss of $1.4 million last year; driven primarily by our release of compared to $27.2 million last year $55.9 million of the valuati
Slide 15: Financials: Adjusted EBITDA and Cash Flow
Financials Adjusted EBITDA1 Cash Flow • Second quarter Adjusted EBITDA was $53.5 million compared to • Net cash provided by operating activities in the second quarter $47.2 million last year was $29.9 million compared to $51.0 million in the comparable period last year, largely driven by a change to
Slide 16: Guidance
Guidance (dollars in millions) 3Q 2023 3Q 2022 Guidance Actuals % Change Total Revenue ~$186-$190 $187.3 ~(1%) - 1% Adjusted EBITDA Margin1 Mid-to-high twenty-percent range FY 2023 FY 2022 Guidance Actuals % Change Total Revenue ~$750-$760 $766.6 ~(2%) – (1%) Adjusted EBITDA Margin1 Mid-to-high twen
Slide 17: Q+A
Q+A
Slide 18: GoodRx helps Americans get the healthcare they need at a price they can afford
GoodRx helps Americans get the healthcare they need at a price they can afford.
Slide 19: Appendix
Appendix
Slide 20: Key Operating Metrics
Key Operating Metrics The following table presents Monthly Active Consumers and Subscription Plans: Three Months Ended June 30, March 31, December 31, September 30, June 30, March 31, (in millions) 2023 2023 2022 2022 2022 2022 Monthly Active Consumers 6.1 6.1 5.9 5.8 5.8 6.4 As of June 30, March 31
Slide 21: Non-GAAP Financial Measures
Non-GAAP Financial Measures The following table presents a reconciliation of net income (loss), the most directly comparable financial measure calculated in accordance with GAAP, to Adjusted EBITDA, and presents net income (loss) margin, the most directly comparable financial measure calculated in a
Slide 22: Non-GAAP Financial Measures
Non-GAAP Financial Measures The following tables present a reconciliation of net income (loss), the most directly comparable financial measures calculated in accordance with GAAP, to Adjusted Net Income: Three Months Ended June 30, March 31, December 31, September 30, June 30, March 31, (dollars in
Slide 23: Non-GAAP Financial Measures
Non-GAAP Financial Measures The following table presents a reconciliation of each non-GAAP, or adjusted, cost and expense measure to its most directly comparable financial measure calculated in accordance with GAAP: Three Months Ended June 30, June 30, (dollars in thousands) 2023 2022 Cost of revenu
Slide 24: Definitions
Definitions • MACs (Monthly Active Consumers) – Refers to the number of • Savings, Saved, or other similar references - Refers to unique consumers who have used a GoodRx code to purchase a the difference between the list price for a particular prescription medication in a given calendar month and ha